Accessibility Menu
Ani Pharmaceuticals logo

Ani Pharmaceuticals

(NASDAQ) ANIP

Current Price$74.84
Market Cap$1.66B
Since IPO (2013)+1,077%
5 Year+118%
1 Year+15%
1 Month-5%

Ani Pharmaceuticals Financials at a Glance

Market Cap

$1.66B

Revenue (TTM)

$883.37M

Net Income (TTM)

$75.85M

EPS (TTM)

$3.35

P/E Ratio

22.13

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Price

$74.84

Volume

10,887

Open

$73.97

Previous Close

$74.84

Daily Range

$73.97 - $75.48

52-Week Range

$56.71 - $99.50

ANIP: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ani Pharmaceuticals

Industry

Pharmaceuticals

Employees

970

CEO

Nikhil Lalwani, MBA

Headquarters

Baudette, MN 56623, US

ANIP Financials

Key Financial Metrics (TTM)

Gross Margin

69%

Operating Margin

13%

Net Income Margin

9%

Return on Equity

15%

Return on Capital

10%

Return on Assets

5%

Earnings Yield

4.52%

Dividend Yield

0.00%

Payout Ratio

1.53%

Stock Overview

Market Cap

$1.66B

Shares Outstanding

22.43M

Volume

10.89K

Short Interest

0.00%

Avg. Volume

451.81K

Financials (TTM)

Gross Profit

$450.64M

Operating Income

$81.23M

EBITDA

$207.27M

Operating Cash Flow

$185.22M

Capital Expenditure

$13.84M

Free Cash Flow

$171.39M

Cash & ST Invst.

$285.58M

Total Debt

$325.19M

Ani Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$247.06M

+29.6%

Gross Profit

$237.56M

+115.4%

Gross Margin

96.15%

N/A

Market Cap

$1.66B

N/A

Market Cap/Employee

$1.85M

N/A

Employees

897

N/A

Net Income

$27.49M

+367.5%

EBITDA

$76.93M

+418.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$39.61M

+91.6%

Accounts Receivable

$281.08M

+26.8%

Inventory

$143.07M

+4.6%

Long Term Debt

$307.93M

-49.9%

Short Term Debt

$17.27M

+88.3%

Return on Assets

5.27%

N/A

Return on Invested Capital

9.56%

N/A

Free Cash Flow

$6.51M

-51.4%

Operating Cash Flow

$30.37M

+91.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TSMRFTsumura & Co.
$23.20+0.00%
GTBIFGreen Thumb Industries Inc.
$6.51-0.31%
ARSUFFagron N.V.
$27.00+0.00%
CASBFCanSino Biologics Inc.
$3.86+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$178.56-0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$45.69-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.35+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.97-0.06%

Questions About ANIP

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.